Japan promote blood screening for breast cancer, cervical cancer, uterine cancer and ovarian cancer

Increasing number of medical institutions in Japan are being introduced by measuring the change in blood analytical concentration of 20 amino acids, the possibility of detecting cancer screening method. Reported that the advantage is that each only about 5 ml of blood, you can also check several types of cancer, is very convenient. Inspected staff were noted to undergo close inspection of the cancer risk is higher.

This check is called “amino indicators of cancer risk screening method (AICS)”. This is the Ajinomoto developed technology for clinical applications. Now you can stomach cancer screening in men, lung cancer, colorectal cancer and prostate cancer, and women’s cancer, lung cancer, colorectal cancer and breast cancer. Furthermore, although they can not individually screened for cervical cancer, uterine cancer and illness possibility of ovarian cancer, but it can determine where the likelihood of suffering from certain cancers.

Normal blood amino acid concentration ratio remained almost certain value, if organs become distorted, then there will be subtle changes in concentration. Vary because of changes in the way and cause organ displays different characteristics, it can be used to determine the likelihood of cancer.

Japan promote blood screening for breast and lung cancer
Japan promote blood screening for breast and lung cancer

AICS 0-10 as the reference value is divided into Class A (0.0-4.9), Class B (5.0-7.9), Class C (8.0-10.0). Although different types of cancer AICS values vary, but the possibility of a class C cancer of 4.0 to 11.6 times the average person.

According to Ajinomoto, and now Japan about 900 medical facilities nationwide are implementing the screening method, and increase year by year. Inspected a total of about 90,000 staff. You can not use health insurance when many medical facilities to implement the screening method, examination fee less than 2 million yen (about 1055 yuan). Plans this spring will add pancreatic cancer, in addition, is exploring the possibility of metabolic syndrome prevalence of cancer and other non-deployment checks.

Leave a Reply